Fundraising Fox
Minerva Biotechnologies
Waltham, US · Delaware corporation
Find your way into Minerva Biotechnologies
Sign up to see every warm intro you have to Minerva Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Minerva Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Minerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
Founders & leadership
CB
Cynthia BamdadCo-founder · CEOCynthia Bamdad is President and Chief Executive Officer of Minerva Biotechnologies, a biotech company in Waltham, Massachusetts developing cancer immunotherapies and regenerative medicine approaches based on understanding shared growth mechanisms between cancer cells and stem cells.
DB
Dr. Bamdad
NS
Normand S SmithSecretary
Board
KK
Kenneth KosikBoard director
RS
Robert StaszewskiBoard director
KR
Kenneth ReedBoard director
JB
James BridgesBoard director
JA
Joseph Anthony NathanBoard director
LC
Lawrence CoolidgeBoard director
NF
Normand F. SmithBoard director
Reported raises · per SEC filings
Form D private placements$64.5M disclosed across 6 rounds · 2014–2023
▶$4.5MraisedDec 2023 · 9 investors · BiotechnologyRule 506(b)
▶$4.5MraisedDec 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth KosikDirector
- James BridgesDirector
- Robert StaszewskiDirector
- Ronald R. AxelrodDirector
- Joseph Anthony NathanDirector
- Lawrence CoolidgeDirector
- Kenneth ReedDirector
- Cynthia BamdadExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $4.5M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$327.7KraisedJan 2023 · 5 investors · BiotechnologyRule 506(b)
▶$327.7KraisedJan 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert StaszewskiDirector
- Lawrence CoolidgeDirector
- Joseph Anthony NathanDirector
- Kenneth ReedDirector
- Ronald R. AxelrodDirector
- Cynthia BamdadExecutive Officer, Director
- Kenneth KosikDirector
- James BridgesDirector
- Offering amount
- $30M
- Amount sold
- $327.7K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.1MraisedJan 2022 · 65 investors · BiotechnologyRule 506(b)
▶$24.1MraisedJan 2022 · 65 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph Anthony NathanDirector
- Cynthia BamdadExecutive Officer, Director
- Kenneth KosikDirector
- James BridgesDirector
- Lawrence CoolidgeDirector
- Kenneth ReedDirector
- Ronald R. AxelrodDirector
- Robert StaszewskiDirector
- Offering amount
- $30M
- Amount sold
- $24.1M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedApr 2019 · 9 investors · BiotechnologyRule 506(b)
▶$4.2MraisedApr 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cynthia BamdadExecutive Officer, Director
- Kenneth KosikDirector
- Robert StaszewskiDirector
- Kenneth ReedDirector
- James BridgesDirector
- Joseph Anthony NathanDirector
- Lawrence CoolidgeDirector
- Normand F. SmithDirector
- Offering amount
- $12M
- Amount sold
- $4.2M
- First sale
- Mar 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$29.3MraisedOct 2018 · 79 investors · BiotechnologyRule 506(b)
▶$29.3MraisedOct 2018 · 79 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth KosikDirector
- Kenneth ReedDirector
- Normand F. SmithDirector
- Lawrence CoolidgeDirector
- James BridgesDirector
- Robert StaszewskiDirector
- Joseph Anthony NathanDirector
- Cynthia BamdadExecutive Officer, Director
- Offering amount
- $31.2M
- Amount sold
- $29.3M
- First sale
- Oct 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2MraisedOct 2014 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Normand S SmithExecutive Officer, Director
- Joseph Anthony NathanDirector
- Cynthia BamdadExecutive Officer, Director
- Kenneth ReedDirector
- Robert StaszewskiDirector
- James BridgesDirector
- Kenneth KosikDirector
- Offering amount
- $30M
- Amount sold
- $2M
- First sale
- Oct 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $209.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $181.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $398K |
| National Science Foundation | Phase II | 2001 | $498.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2001 | $435.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2001 | $388K |
| National Science Foundation | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $130K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $100K |
| National Science Foundation | Phase I | 2000 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Minerva Biotechnologies do?
- Minerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
- Who founded Minerva Biotechnologies?
- Minerva Biotechnologies was founded by Cynthia Bamdad, Dr. Bamdad.
- How much funding has Minerva Biotechnologies raised?
- Minerva Biotechnologies has disclosed $64.5M raised across 6 rounds.
- Where is Minerva Biotechnologies headquartered?
- Minerva Biotechnologies is headquartered in Waltham, US.